1,4-Dihydropyrazolo[4,3-d]imidazole phenyl derivatives: A novel type II Raf kinase inhibitors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, Hana | - |
dc.contributor.author | Jung, Yunkyung | - |
dc.contributor.author | Kim, Hwan | - |
dc.contributor.author | Lee, Junghun | - |
dc.contributor.author | Oh, Chang-Hyun | - |
dc.contributor.author | Yoo, Kyung Ho | - |
dc.contributor.author | Sim, Taebo | - |
dc.contributor.author | Hah, Jung-Mi | - |
dc.date.accessioned | 2021-06-23T13:04:19Z | - |
dc.date.available | 2021-06-23T13:04:19Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2010-06 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/39714 | - |
dc.description.abstract | The synthesis of a novel series of 1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives 1a-b, 2a-v and their antiproliferative activities against A375P and WM3629 human melanoma cell line were described. Most compounds showed competitive antiproliferative activities to sorafenib, the reference standard. Among them, pyrazoloimidazole phenyl urea compounds 2a, 2d, 2g, 2i, 2t exhibited potent activities on WM3629 cell lines (IC50 = 0.56-0.86 mu M). Especially, 2t was found to be a potent and selective C-Raf inhibitor, showing a possibility as melanoma therapeutics. (C) 2010 Elsevier Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.title | 1,4-Dihydropyrazolo[4,3-d]imidazole phenyl derivatives: A novel type II Raf kinase inhibitors | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hah, Jung-Mi | - |
dc.identifier.doi | 10.1016/j.bmcl.2010.04.039 | - |
dc.identifier.scopusid | 2-s2.0-77954218062 | - |
dc.identifier.wosid | 000278208200078 | - |
dc.identifier.bibliographicCitation | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, v.20, no.12, pp.3805 - 3808 | - |
dc.relation.isPartOf | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.title | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.volume | 20 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 3805 | - |
dc.citation.endPage | 3808 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.subject.keywordPlus | B-RAF | - |
dc.subject.keywordPlus | BRAF | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | MELANOMA | - |
dc.subject.keywordPlus | DESIGN | - |
dc.subject.keywordPlus | DISCOVERY | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | CRAF | - |
dc.subject.keywordAuthor | 1,4-Dihydropyrazolo[4,3-d]imidazole | - |
dc.subject.keywordAuthor | phenyl derivatives | - |
dc.subject.keywordAuthor | Antiproliferative activity | - |
dc.subject.keywordAuthor | Melanoma cell line | - |
dc.subject.keywordAuthor | Selectivity | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0960894X10005093?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.